Brief: Spectral provides update on FDA meeting regarding PMA submission for toraymyxin

Spectral Medical

31/10/2017 12:00

Oct 31 (Reuters) - Spectral Medical Inc  EDT.TO : 
    * Spectral provides update on FDA meeting regarding its pma 
submission for toraymyxin(tm) 
    * Spectral Medical - meeting with fda consisted of 
discussion of 
issues identified by FDA for toraymyxin after first 100 days of 
review 
    * Spectral Medical - co committed to a timely response to 
fda's 
questions, which is expected to occur during month of November 
2017 
 
Source text for Eikon:  ID:nCCNgNjFda  
Further company coverage:  EDT.TO  
 
 ((bangalore.newsroom@thomsonreuters.com;))